DAFNA Capital Management LLC Has $12.59 Million Position in AxoGen, Inc. $AXGN

Key Points

• DAFNA Capital Management LLC reduced its stake in AxoGen, Inc. by 19.6% during the first quarter, now holding approximately 3.6% of the company's total shares.
• Other institutional investors have also increased their positions in AxoGen, with Driehaus Capital Management LLC boosting holdings by 22.8% and Trexquant Investment LP raising theirs by an astonishing 827.7%.
• The stock currently has a consensus rating of "Buy" among analysts, with a target price set at $26.00, despite a recent decrease from $26.00 to $24.00 by Canaccord Genuity Group.

DAFNA Capital Management LLC lessened its holdings in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 19.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 680,782 shares of the medical equipment provider's stock after selling 166,100 shares during the quarter. AxoGen makes up about 3.6% of DAFNA Capital Management LLC's holdings, making the stock its 10th largest position. DAFNA Capital Management LLC owned 1.50% of AxoGen worth $12,594,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in AxoGen by 4.6% in the first quarter. Vanguard Group Inc. now owns 2,538,607 shares of the medical equipment provider's stock valued at $46,964,000 after acquiring an additional 112,679 shares in the last quarter. Driehaus Capital Management LLC increased its holdings in AxoGen by 22.8% in the first quarter. Driehaus Capital Management LLC now owns 1,172,029 shares of the medical equipment provider's stock valued at $21,683,000 after buying an additional 217,590 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in shares of AxoGen by 21.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,001,217 shares of the medical equipment provider's stock worth $18,523,000 after purchasing an additional 174,681 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of AxoGen by 13.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider's stock worth $12,735,000 after purchasing an additional 91,984 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of AxoGen by 2.2% during the 4th quarter. Deutsche Bank AG now owns 594,843 shares of the medical equipment provider's stock worth $9,803,000 after purchasing an additional 12,604 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company's stock.

AxoGen Stock Performance

Shares of NASDAQ:AXGN traded down $0.10 during trading hours on Wednesday, hitting $15.61. The stock had a trading volume of 833,831 shares, compared to its average volume of 830,301. AxoGen, Inc. has a 1-year low of $9.22 and a 1-year high of $21.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14. The firm has a market capitalization of $718.26 million, a price-to-earnings ratio of -156.08 and a beta of 1.03. The stock's fifty day simple moving average is $13.26 and its 200 day simple moving average is $14.37.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Canaccord Genuity Group decreased their target price on shares of AxoGen from $26.00 to $24.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Wall Street Zen upgraded shares of AxoGen from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, AxoGen has a consensus rating of "Buy" and an average price target of $26.00.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.